Fourth quarter sales of filtration and specialty products were up 3% compared to the prior year. For the year, sales were up 10% with growth across all key application areas and the effect of foreign currency translation. Segment operating income in the quarter was 28% of sales, slightly below the 30% level last year, due to the cost of added PUREMA hemodialysis membrane capacity in 2011, which will allow us to participate in the industry growth going forward.Read the rest of this transcript for free on seekingalpha.com
Polypore's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.